Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
Heidelberg University · University Hospital Heidelberg · +14 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,265
total citations
- FWCI
- 46.06
- Percentile
- 100%
- References
- 19
Citations per year
Authors
13- ASAndreas SchneeweißCorresponding
Heidelberg University, University Hospital Heidelberg, National Center for Tumor Diseases
- SCStephen Chia
BC Cancer Agency, University of British Columbia
- THTamas Hickish
Royal Bournemouth Hospital, Bournemouth University
- VHV. Harvey
Auckland City Hospital
- AEAlexandru Eniu
Institute of Oncology Prof. Dr. Ion Chiricuta
Topics & keywords
Topics
Keywords
- Medicine
- Epirubicin
- Pertuzumab
- Trastuzumab
- Breast cancer
- Internal medicine
- Anthracycline
- Docetaxel
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.